Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan versus valsartan for left ventricular remodelling after myocardial infarction
2017-003460-13Phase 3Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sacubitril + valsartan and valsartan in left ventricular systolic dysfunction (LVSD), heart failure (HF) and myocardial infarction (MI) (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Change in indexed left ventricular end-systolic volume. Status: unknown.
02
Drugs
sacubitril + valsartanvalsartan
03
Conditions
left ventricular systolic dysfunction (LVSD)heart failure (HF)myocardial infarction (MI)
Beyond the preview
Go deeper on 2017-003460-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003460-13.